{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000102","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.005615+00:00","generated_at":"2026-05-17T13:58:26.186960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial","bullets":["Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.","94% overall survival at 6 months in Phase 2a of atebimetinib + mGnP in first-line pancreatic cancer (n=34); median OS not reached.","Third-line pancreatic cancer patient on atebimetinib monotherapy >18 months with confirmed partial response and 34% tumor reduction.","US composition of matter patent granted for atebimetinib provides exclusivity into 2042; pivotal trial expected in 2026.","Cash runway sufficient into 2026; End of Phase 2 meeting request submitted to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000102","json":"https://secwatch.observer/filing/0001790340-25-000102.json","markdown":"https://secwatch.observer/filing/0001790340-25-000102.md","text":"https://secwatch.observer/filing/0001790340-25-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/0001790340-25-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:26.186960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}